<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305808</url>
  </required_header>
  <id_info>
    <org_study_id>0014-20-HMO</org_study_id>
    <nct_id>NCT04305808</nct_id>
  </id_info>
  <brief_title>Characterization of Vaginal, Urinary and Fecal Microbiomes in Women With Recurrent Urinary Tract Infections</brief_title>
  <official_title>Characterization of Vaginal, Urinary and Fecal Microbiomes in Women With Recurrent Urinary Tract Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives are to evaluate whether variations in vaginal and/or urinary and/or fecal&#xD;
      microbiome predispose postmenopausal women to recurrent cystitis. This will be explored using&#xD;
      comparison of microbiome profiles between those with recurrent UTI compared to age-matched&#xD;
      women without recurrent UTI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients and age-matched control subjects will be recruited from the Urogynecology clinic in&#xD;
      Hadassah Mt Scopus and the gynecology clinic, respectively.&#xD;
&#xD;
      After assessment of inclusion and exclusion criteria and patient's consent to participate, a&#xD;
      history intake (detailing demographics, medical history, risk factors for rUTI etc.) and&#xD;
      gynecological examination will be conducted as part of the usual assessment in the clinic.&#xD;
&#xD;
      Vaginal, urine and fecal samples for microbiome molecular analysis will be collected during&#xD;
      clinic visits, given at least one month without antibiotics before samples collection, using&#xD;
      agreed protocols and will be kept for future evaluation. Urine will be collected for&#xD;
      urinalysis and for a urine culture.&#xD;
&#xD;
      In addition, urine cultures, as well as vaginal, urine and fecal samples for molecular&#xD;
      analysis will be collected during an acute UTI episode from the same patients.&#xD;
&#xD;
      Healthy patients (the control group) will be examined only once.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of the microbiome using molecular methods.</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of microbiome profiles between those with rUTI compared to healthy controls.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Urinary Tract Infections</condition>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Recurrent Urinary tract infection</arm_group_label>
    <description>Menopausal women, with two or more documented, culture-positive infections in the last six months or ≥3 infections in the last year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Menopausal women, without prior history of UTIs or other urologic abnormalities.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Vaginal, urine and fecal samples for microbiome molecular analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Menopausal women, with recurrent UTI and age-matched menopausal women without recurrent&#xD;
        UTI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients' inclusion criteria:&#xD;
&#xD;
          -  Menopausal status&#xD;
&#xD;
          -  Two or more documented, culture-positive infections in the last six months or ≥3&#xD;
             infections in the last year Patients' exclusion criteria&#xD;
&#xD;
          -  Neurogenic bladder condition&#xD;
&#xD;
          -  Known immunodeficiencies&#xD;
&#xD;
          -  Usage of antibiotics or probiotics within the previous month&#xD;
&#xD;
          -  Known renal calculi or anatomic malformations&#xD;
&#xD;
        Control subjects- Inclusion criteria:&#xD;
&#xD;
          -  Menopausal status&#xD;
&#xD;
          -  Sterile urine cultures, normal urinalysis, and negative sexually-transmitted PCR urine&#xD;
             assay&#xD;
&#xD;
        Control subjects- Exclusion criteria:&#xD;
&#xD;
        - A prior history of UTIs or other urologic abnormalities.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahinoam Lev-Sagie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahinoam Lev-Sagie, MD</last_name>
    <phone>97225844000</phone>
    <email>levsagie@netvision.net.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9765422</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahinoam Lev-Sagie, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Ahinoam Lev-Sagie</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

